HLB

028300KOSDAQ의료용품 및 기타 의약 관련제품 제조업

52.9 / 100

Reference Date: 2026-04-13

Financial Score12.5 / 40

News Sentiment13.4 / 25

Momentum17.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Surged 17.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HLB operates in four key sectors: healthcare, biotechnology, shipbuilding, and media commerce. The company produces and sells a range of products, including in-vitro diagnostic medical devices, oncology drugs like Rivoceranib and RLY-4008, specialty ships, and beauty devices. In the biotechnology sector, the company focuses on innovative drug development, while the shipbuilding division designs and manufactures specialty vessels and safety equipment.

Number of Employees

151people

Average Salary

60.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.894.0Point

PBR

15.29Industry Average 1.620.0Point

9.4x industry avg (risky)

ROE

-41.07Industry Average -4.893.5Point

8.4x industry avg (excellent)

Debt Ratio

17.82Industry Average 8.880.0Point

2.0x industry avg (risky)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲41.2% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -30.1% (declining, 3yr)

Detailed News Sentiment

29 totalPositive 2Neutral 22Negative 0Average Sentiment Score 54.2

Detailed Momentum

52-week position6.0Point

52w upper range (65%)

Current 56,800Won52-week high 67,20052-week low 37,000

1-month return6.0Point

1m +17.60% (strong rise)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0

Neutral주요사항보고서(전환사채권발행결정)2026-04-07
Neutral대표이사변경2026-03-31
Neutral정기주주총회결과2026-03-31
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral기업설명회(IR)개최2026-03-25